well, they'll be taking on more risk if that money ends up not being enough to support early stage startups. And, it makes the deal even more difficult to swall

well, they'll be taking on more risk if that money ends up not being enough to support early stage startups. And, it makes the deal even more difficult to swallow for hardtechs/biotechs/moonshots, and potentially making it worse for those companies could decrease diversification opportunities? still a better move for YC than the companies getting funded